PAX9 and B-cell chronic lymphocytic leukemia: Since levels of expression of either PAX9 or CRY1 did not show significant difference in CLL patients when compared to healthy controls but rather between patients subgrouped on the basis of the IGHV mutational status, it is plausible that these two genes may be involved in progression of CLL rather than development of the disease.